BRPI0511694A - composições de liberação controlada - Google Patents

composições de liberação controlada

Info

Publication number
BRPI0511694A
BRPI0511694A BRPI0511694-5A BRPI0511694A BRPI0511694A BR PI0511694 A BRPI0511694 A BR PI0511694A BR PI0511694 A BRPI0511694 A BR PI0511694A BR PI0511694 A BRPI0511694 A BR PI0511694A
Authority
BR
Brazil
Prior art keywords
controlled release
mini
implant
precipitate
agonist
Prior art date
Application number
BRPI0511694-5A
Other languages
English (en)
Inventor
Malcom Brandon
Serge R Martinod
Original Assignee
Smart Drug Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004902893A external-priority patent/AU2004902893A0/en
Application filed by Smart Drug Systems Inc filed Critical Smart Drug Systems Inc
Publication of BRPI0511694A publication Critical patent/BRPI0511694A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Abstract

COMPOSIçõES DE LIBERAçãO CONTROLADA Um mecanismo de liberação controlada incluindo pelo menos um mini-implante ou precipitado de liberação controlada; o ou cada mini-implante ou precipitado incluindo, um material de suporte de liberação controlada; e uma composição farmacêutica incluindo um componente de agonista e/ou antagonista de Hormónio Liberador de Hormónio Luteinizante (LHRH) o tamanho e/ou número e/ou carga útil do mini-implante(s) ou precipitado(s) fornecendo, liberação de agonista e/ou antagonista de LHRH em, ou acima de um nível limite desejado para o tratamento de uma indicação selecionada, o mecanismo fornecendo ordem aproximadamente zero de liberação do agonista e/ou antagonista de LHRH.
BRPI0511694-5A 2004-05-31 2005-05-30 composições de liberação controlada BRPI0511694A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004902893A AU2004902893A0 (en) 2004-05-31 Sustained release composition
PCT/AU2005/000766 WO2005117934A1 (en) 2004-05-31 2005-05-30 Sustained release composition

Publications (1)

Publication Number Publication Date
BRPI0511694A true BRPI0511694A (pt) 2008-01-08

Family

ID=35462731

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511694-5A BRPI0511694A (pt) 2004-05-31 2005-05-30 composições de liberação controlada

Country Status (9)

Country Link
US (2) US20080044450A1 (pt)
EP (1) EP1755636A1 (pt)
JP (1) JP2008500973A (pt)
CN (2) CN101001640A (pt)
AR (1) AR049198A1 (pt)
BR (1) BRPI0511694A (pt)
CA (1) CA2568641A1 (pt)
WO (1) WO2005117934A1 (pt)
ZA (1) ZA200700068B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100003297A1 (en) * 2005-08-11 2010-01-07 Massachusetts Institute Of Technology Implantable Drug Delivery Device and Methods of Treating Male Genitourinary and Surrounding Tissues
WO2009033807A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43
EP2246063A1 (en) 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. Sustained release formulations comprising GnRH analogues
AU2010265866B2 (en) 2009-06-26 2012-07-12 Taris Biomedical Llc Solid drug tablets for implantable drug delivery devices
CN102145160A (zh) * 2011-03-07 2011-08-10 深圳市健元医药科技有限公司 一种lhrh拮抗剂注射用的缓释植入制剂
EP3131532A1 (de) 2014-04-16 2017-02-22 Veyx-Pharma GmbH Veterinärpharmazeutische zusammensetzung und deren verwendung
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
CN107778354B (zh) * 2016-08-25 2021-03-02 成都圣诺生物制药有限公司 一种合成阿巴瑞克的方法
US20210113664A1 (en) * 2018-06-25 2021-04-22 Titan Pharmaceuticals, Inc. Implants for release of lipophilic or amphiphilic pharmaceutical substances

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
EP1104296B1 (en) * 1998-07-20 2012-06-13 Peptech Animal Health Pty Limited Bioimplant formulation
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
AUPR602501A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release pharmaceutical composition
AUPR610501A0 (en) * 2001-07-04 2001-07-26 Smart Drug Systems Inc Treatment of parasitic disease
BR0212052A (pt) * 2001-09-11 2004-08-17 Smart Drug Systems Inc Preparação de composição farmacêutica de liberação prolongada
JP2005522418A (ja) * 2002-01-24 2005-07-28 スマート ドラッグ システムズ インコーポレイティド 徐放性医薬組成物

Also Published As

Publication number Publication date
US20080044450A1 (en) 2008-02-21
CN101683317A (zh) 2010-03-31
JP2008500973A (ja) 2008-01-17
CN101001640A (zh) 2007-07-18
AR049198A1 (es) 2006-07-05
WO2005117934A1 (en) 2005-12-15
CA2568641A1 (en) 2005-12-15
EP1755636A1 (en) 2007-02-28
ZA200700068B (en) 2008-06-25
US20110142901A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
BRPI0511694A (pt) composições de liberação controlada
CL2007003266A1 (es) Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
BRPI0612674A8 (pt) preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio, e, método para a profilaxia ou tratamento de hipertensão
BRPI0718523B8 (pt) Forma de dosagem, e, método para preparar a forma de dosagem
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
EP1898849A4 (en) NEW PROGRAMS FOR CONTRAZEPTIVE DEVICES WITH CONTROLLED DRUG DELIVERY
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
CL2008002051A1 (es) Compuestos derivados de isoxazol-4-metoxi, triazol-4-metoxi o pirazol-4-metoxi, con actividad agonista del receptor x de farnesoide (fxr); composicion farmaceutica que los contiene; y el uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento de dislipidemia y enfermedades relacionadas.
WO2006014606A3 (en) Medical devices containing copolymers with graft copolymer endblocks for drug delivery
CL2008003271A1 (es) Compuesto (2r)-2-[[(4-clorofenil)sulfonil][[2-fluoro-4-(1,2,4-oxadiazol-3-il)fenil]metil]amino]-5,5,5-trifluoropentanamida; composiciones farmaceuticas que lo contienen; y su uso en el tratamiento o retardo de la aparicion de la enfermedad de alzheimer, angiopatia amiloide cerebral, deterioro cognitivo leve y/o sindrome de down.
EA200702116A1 (ru) Фармацевтическая дозированная форма (варианты) с контролируемым высвобождением антигипергликемического средства в комбинации с производным тиазолидиндиона
DK1734971T3 (da) Indretning på polymerbasis med forsinket frigivelse
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2012000166A1 (es) Compuesto (11beta,17beta)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; y su uso para el tratamiento y/o la prevencion de fibroides uterinos, endometriosis, sangrados menstruales severos, meningiomas, cancer de mama hormonodependiente y de trastornos asociados a la menopausia, entre otros.
CL2007002888A1 (es) Compuestos derivados de n-metansulfonilamino amidas, inhibidores de metaloproteasas de matriz; composicion farmaceutica; y uso para el tratamiento de un trastorno de proliferacion celular.
BRPI0818448A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5.
WO2007038466A3 (en) Treatment of bipolar disorder utilizing anti-fungal compositions
CL2011000570A1 (es) Compuestos derivados de 3-(4-ciano-fenil)-pirazol-5-carboxamida, moduladores del receptor de progesterona; composicion farmaceutica; y su uso para el tratamiento de endometriosis, fibromiomas uterinos, dismenorrea primaria o secundaria, entre otras.
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
HK1096293A1 (en) Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
MX2009010167A (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol-7-carboxilato y un agente para el control del ph.
CL2009000964A1 (es) Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]